Theriva Biologics Company Insiders
| TOVX Stock | USD 1.47 0.15 9.26% |
Theriva Biologics employs about 22 people. The company is managed by 7 executives with a total tenure of roughly 52 years, averaging almost 7.0 years of service per executive, having 3.14 employees per reported executive. Break down of Theriva Biologics' management performance can provide insight into the company performance.
Theriva |
Theriva Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2498) % which means that it has lost $0.2498 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5906) %, meaning that it created substantial loss on money invested by shareholders. Theriva Biologics' management efficiency ratios could be used to measure how well Theriva Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.58 in 2025. Return On Capital Employed is likely to rise to -0.48 in 2025. At this time, Theriva Biologics' Asset Turnover is fairly stable compared to the past year.Common Stock Shares Outstanding is likely to rise to about 1.1 M in 2025, whereas Net Loss is likely to drop (23.8 M) in 2025.
Theriva Biologics Workforce Comparison
Theriva Biologics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 454. Theriva Biologics holds roughly 22.0 in number of employees claiming about 5% of equities under Health Care industry.
Theriva Biologics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theriva Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theriva Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Theriva Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kraws Jeffrey J over a year ago Acquisition by Kraws Jeffrey J of 110000 shares of Theriva Biologics subject to Rule 16b-3 |
Theriva Biologics Notable Stakeholders
A Theriva Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Theriva Biologics often face trade-offs trying to please all of them. Theriva Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Theriva Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Steven CPA | CFO, CEO | Profile | |
| Vincent Perrone | Director Communication | Profile | |
| Frank Tufaro | Chief Officer | Profile | |
| Vince Wacher | Head Development | Profile | |
| Lara Guzman | Director Operations | Profile | |
| Ramon Alemany | Senior Board | Profile | |
| Michael MD | Senior Development | Profile |
About Theriva Biologics Management Performance
The success or failure of an entity such as Theriva Biologics often depends on how effective the management is. Theriva Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Theriva management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Theriva management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.55) | (0.58) | |
| Return On Capital Employed | (0.51) | (0.48) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.42) | (0.44) |
Please note, the imprecision that can be found in Theriva Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Theriva Biologics. Check Theriva Biologics' Beneish M Score to see the likelihood of Theriva Biologics' management manipulating its earnings.
Theriva Biologics Workforce Analysis
Traditionally, organizations such as Theriva Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Theriva Biologics within its industry.Theriva Biologics Manpower Efficiency
Return on Theriva Biologics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 834K | |
| Net Loss Per Executive | 2.6M | |
| Working Capital Per Employee | 939.3K | |
| Working Capital Per Executive | 3M |
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.